Industry Press Update

by Chris on February 17, 2011

in Press Release

02/17/2011 – 09:00 AM
miRagen Therapeutics Receives Orphan Drug Designation for MGN-4893 for the Treatment of Polycythemia Vera

02/10/2011 – 04:00 PM
Alnylam to Webcast Conference Call Discussing Fourth Quarter and 2010 Financial Results

02/10/2011 – 08:30 AM
Regulus Therapeutics to Present Multiple Platform and Pipeline Advancements at the Keystone Symposium on microRNAs

02/08/2011 – 04:00 PM
Alnylam to Webcast Presentation at the 13th Annual BIO CEO & Investor Conference

01/27/2011 – 07:15 AM
RXi Pharmaceuticals Announces Positive Initial Results in microRNA Therapeutics

01/25/2011 – 08:00 AM
Alnylam Receives Positive Opinion for Orphan Drug Designation from European Medicines Agency for ALN-TTR01, an RNAi Therapeutic for the Treatment of Transthyretin-Mediated Amyloidosis

01/25/2011 – 07:30 AM
NanoString Technologies Introduces Multiplexed Assay Kit for Mouse microRNA Analysis

Leave a Comment

Previous post:

Next post: